AVAC Vietnam

What AVAC Vietnam does

AVAC Vietnam (Công ty Cổ phần AVAC Việt Nam) is a privately held Vietnamese veterinary vaccine manufacturer founded in 2012 and headquartered in Như Quỳnh, Hưng Yên Province. The company develops and commercializes a portfolio of more than 30 licensed veterinary vaccines covering pigs (swine), cattle and buffalo, and poultry/waterfowl, with primary disease targets including African Swine Fever (ASF), Porcine Epidemic Diarrhea (PED), Porcine Reproductive and Respiratory Syndrome (PRRS), Classical Swine Fever (CSF), Foot and Mouth Disease (FMD), Lumpy Skin Disease (LSD), Duck Viral Hepatitis, and Duck Viral Enteritis. Its flagship product, AVAC ASF LIVE, became the world's first commercially approved African Swine Fever vaccine when it received full circulation and export authorization in Vietnam on July 24, 2023, after an initial controlled-release approval in July 2022.

AVAC's product platform centers on live attenuated and inactivated vaccine formats produced via cell culture, fermenter-based fermentation, and freeze-drying. Its core technical differentiator is the proprietary DMAC (Diep's Macrophage) continuous cell line — derived from pig-embryo macrophages and named after founder and CEO Dr. Nguyễn Văn Điệp — which enables stable propagation of African Swine Fever virus for vaccine manufacturing and is protected at the Vietnamese Office of Intellectual Property. The ASF-G-ΔMGF vaccine strain used in AVAC ASF LIVE was developed through a gene-deletion approach removing six MGF360/MGF505 genes; the underlying gene-deleted live attenuated vaccine platform underpins the broader R&D pipeline. The vaccine master seed is registered in the global gene bank (accession PP529961), and AVAC LSD LIVE undergoes annual quality testing at the African Union – Pan African Veterinary Vaccine Centre (AU-PANVAC), a WOAH reference laboratory.

AVAC operates a sales-led go-to-market model reaching smallholder livestock farmers and large commercial enterprises through direct field sales, distribution partner APHARMA (with QR-code product authentication), and provincial veterinary departments supporting national vaccination programs across 45 provinces and cities. Domestic deployment has covered more than 35,000 pig farms and over 3 million ASF vaccine doses, and the company has captured over 90% market share in Vietnam for Lumpy Skin Disease vaccine. Export channels are anchored by the Philippines Bureau of Animal Industry (BAI), which imported 460,000 ASF doses after July 2024 approval, and Indonesia's PT Putra Perkasa Genetika following April 2025 approval, with 500,000 ASF doses targeted for Indonesia in 2025; AVAC is also the first Vietnamese firm to export LSD vaccine to South Korea (1.1 million doses). Diagnostic testing services and an imported-product distribution line round out the offering. Pricing is per-dose (approximately 60,000 VND for AVAC ASF LIVE) and revenue and headcount figures are not publicly disclosed.

Name

AVAC Vietnam

Legal name

CÔNG TY CỔ PHẦN AVAC VIỆT NAM

Website

https://avac.com.vn

Company type

Private

Founded year

2012

Operating status

Operating

Short description

AVAC Vietnam is a privately held Vietnamese veterinary vaccine manufacturer developing live attenuated and inactivated vaccines, including AVAC ASF LIVE — the world's first approved African Swine Fever vaccine — serving pig, cattle, and poultry farmers domestically and in export markets.

Ownership category

akta.pro rank

Product category

Veterinary Vaccines

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Livestock Vaccines (Cattle, Swine, Sheep & Goats) (HLAMAKAB)

akta.pro secondary industries

Veterinary Vaccines (Biologics) (HLAMAEAL), Veterinary Vaccines (HLAIAEAH), Poultry Vaccines (HLAMAKAC), Vaccine R&D, Clinical/Field Trials & Regulatory Affairs (HLAMAKAM), Vaccine Programs & Tendering (Government/NGO, Eradication Campaigns) (HLAMAKAO)

Keywords

• Veterinary vaccines
• Livestock vaccine manufacturing
• Animal disease prevention
• Swine vaccines
• Live attenuated vaccines

Headquarters

HQ city

Hanoi

HQ country

Vietnam

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Veterinary Vaccine Sales - Domestic: Sale of veterinary vaccines for pigs, poultry, and livestock including ASF, FMD, PRRS, PED, CSF, LSD, and other diseases to Vietnamese farmers and through distribution networks.
2. Veterinary Vaccine Export: Export of vaccines including ASF vaccine to Philippines, Indonesia, and other countries. Indonesia approved AVAC ASF LIVE in April 2025 with 100,000 doses initially and 500,000 doses planned for 2025.
3. Diagnostic Services: Diagnostic testing and analysis services for animal diseases.

Pricing tiers

Go-to-market motion1 record

Distribution channels6 records

Marketing channels6 records

Core offering

AVAC Vietnam researches, develops, and manufactures veterinary vaccines for livestock including pigs, cattle/buffalo, and poultry/waterfowl. The portfolio spans live attenuated, inactivated, and oil-emulsion vaccines for African Swine Fever (ASF), Foot and Mouth Disease (FMD), Classical Swine Fever (CSF), Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine Epidemic Diarrhea (PED), Lumpy Skin Disease (LSD), Duck Viral Hepatitis (DVH), Duck Viral Enteritis (DVE), and Haemorrhagic Septicaemia. The company also offers diagnostic and testing services and distributes imported veterinary vaccines.

Product overview

AVAC Vietnam is a veterinary vaccine pharmaceutical company offering a portfolio of live attenuated, inactivated, and oil-emulsion vaccines across three animal segments: pigs (swine), poultry/waterfowl, and livestock (cattle/buffalo). The core product line is anchored by AVAC ASF LIVE, Vietnam's first commercially approved African Swine Fever vaccine (July 2022) using proprietary gene-deletion technology on the DMAC cell line. The pig portfolio also includes AVAC PED LIVE (PED), Avac PRRS Live (PRRS), Avac CSF Live (Classical Swine Fever), and Avac V6 FMD Emulsion (Foot and Mouth Disease). The cattle/buffalo portfolio features AVAC LSD LIVE (Lumpy Skin Disease — January 2023, over 90% market share in Vietnam) and two Haemorrhagic Septicaemia vaccines (oil-emulsion and alum-adjuvanted formulations). The poultry portfolio includes AVAC DVH LIVE (Duck Viral Hepatitis Serotype I) and AVAC DVE LIVE (Duck Viral Enteritis Serotype C). Beyond manufacturing, the company offers diagnostic and testing services and distributes imported vaccine products. The company maintains a "People Grade A – System Grade A – Quality Grade A" philosophy.

Differentiator

Problem solved

Functional benefit

Brands

• AVAC ASF LIVE: Live attenuated freeze-dried vaccine for African Swine Fever (ASF) prevention in pigs
• AVAC LSD LIVE
• AVAC PED LIVE
• Avac PRRS Live
• Avac CSF Live
• Avac - V6 FMD Emulsion
• AVAC CATTLE - HS EMULSION
• AVAC DVH LIVE
• AVAC DVE LIVE

Products and services

• AVAC ASF LIVE (African Swine Fever Vaccine) Live attenuated freeze-dried vaccine against African Swine Fever (ASF) genotype II, using the ASF-G-ΔMGF strain with 6 MGF genes deleted, cultured on the proprietary DMAC macrophage cell line. Indicated for healthy pigs from 4 weeks of age; single intramuscular dose provides immunity lasting up to 5 months.
• AVAC LSD LIVE (Lumpy Skin Disease Vaccine) Live attenuated freeze-dried vaccine against Lumpy Skin Disease (LSD) in cattle and buffalo, using the Neethling strain. Immunity develops 3 weeks post-vaccination and lasts at least 12 months. Holds over 90% market share for LSD vaccine in Vietnam and is exported to South Korea.
• AVAC PED LIVE (Porcine Epidemic Diarrhea Vaccine) Live attenuated freeze-dried vaccine against Porcine Epidemic Diarrhea (PED), strain Avac/98 (Genotype 1), cultured on Vero cells. Administered intramuscularly to pregnant sows and gilts to protect neonatal piglets via passive immunity from colostral IgA.
• Avac PRRS Live (Porcine Reproductive and Respiratory Syndrome Vaccine) Live attenuated freeze-dried vaccine against Porcine Reproductive and Respiratory Syndrome (PRRS), strain PRRS/RTD1/2012, cultured on Marc-145 cells. Indicated for pigs from 3 weeks of age; provides cross-protection against heterologous strains including highly virulent variants and reduces PRRS viremia.
• Avac CSF Live (Classical Swine Fever Vaccine) Live attenuated freeze-dried vaccine against Classical Swine Fever (CSF), strain C, cultured on PK-15 cell line. Administered to healthy pigs by intramuscular or subcutaneous injection behind the ear. Primary vaccination at 30-35 days of age with booster at 60-65 days; immunity lasts 6 months.
• Avac V6 FMD Emulsion (Foot and Mouth Disease Vaccine Type O) Inactivated oil-emulsion vaccine against Foot and Mouth Disease (FMD) type O, strain RAH06/FMD/O-135, providing cross-protection against 30 subtypes including Mya-98, PanAsia, Cathay, and Ind2001. Indicated for cloven-hoofed animals (pigs, cattle, buffalo, sheep, goats). Administered intramuscularly every 6 months.
• AVAC CATTLE - HS EMULSION (Haemorrhagic Septicaemia Oil-Emulsion Vaccine) Inactivated oil-emulsion vaccine against Haemorrhagic Septicaemia (pasteurellosis) in cattle and buffalo, using Pasteurella boviseptica and Pasteurella bubaliseptica strains produced via fermenter technology. Administered intramuscularly to cattle and buffalo from 2 months of age; booster every 6-12 months depending on disease status.
• Haemorrhagic Septicaemia Vaccine (Alum-Adjuvanted) Inactivated alum-precipitated vaccine against Haemorrhagic Septicaemia in cattle and buffalo, using Pasteurella boviseptica and Pasteurella bubaliseptica produced via fermenter technology. Administered to cattle and buffalo from 6 months of age by intramuscular or subcutaneous injection; booster every 6 months.
• AVAC DVH LIVE (Duck Viral Hepatitis Serotype I Vaccine) Live attenuated freeze-dried vaccine against Duck Viral Hepatitis (DVH) Serotype I in ducks and muscovys, produced on SPF chicken eggs. Administered by subcutaneous, intramuscular injection, or oral route. Immunity develops within 3-5 days, peaks at 7 days, and lasts 1 month.
• AVAC DVE LIVE (Duck Viral Enteritis Vaccine) Live attenuated freeze-dried vaccine against Duck Viral Enteritis (DVE) Serotype C in ducks and muscovys, produced on SPF chicken eggs. Indicated for ducks and muscovys of all ages; can be used for mass vaccination in outbreak situations via double-dose oral administration.
• Diagnostic and Testing Services Diagnostic testing and analysis services for animal diseases, supporting disease detection and monitoring for livestock farms. Listed as a distinct service category on the company's product/service menu.
• Imported Veterinary Vaccine Distribution Distribution of imported veterinary vaccine products alongside AVAC's domestic product range, as listed in the product category navigation on the company website.

Quantifiable outcome

• 97-99% protection rate against ASF genotype II in controlled trials
• +4 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Seven partnerships are on record, tiered core and moderate.

• Bureau of Animal Industry (BAI) - PhilippinescoreStrategic or Co-development Partner · 1 July 2024Philippines BAI conducted vaccine trials in laboratory scale and 10 farms from February 2023. Government approved AVAC ASF LIVE in July 2024, with 460,000 doses imported.
• PT Putra Perkasa Genetika (Indonesia)coreChannel Partner/ Reseller/ Distributor · 1 October 2023Partnership signed in October 2023 for distribution of AVAC ASF vaccine in Indonesia. Indonesia officially approved AVAC ASF LIVE on April 23, 2025, with first import of 100,000 doses in May 2025 and 500,000 doses planned for full year 2025.
• USDA/ARS (United States Department of Agriculture/Agricultural Research Service)coreTechnology or Integration · 1 January 2020Technology transfer partnership for ASF vaccine development. USDA ARS provided 3 attenuated ASF virus strains developed through gene deletion. This access was crucial for AVAC to invest in and launch the ASF vaccine development project.
• APHARMA (Vietnam)coreChannel Partner/ Reseller/ DistributorDistribution partner in Vietnam for AVAC vaccines. APHARMA provides QR code tracking for product authenticity and organizes training workshops with local veterinary staff and farmers.
• African Union - Pan African Veterinary Vaccine Centre (AU-PANVAC)moderateTechnology or IntegrationAnnual quality testing of AVAC LSD vaccine at AU-PANVAC, an OIE reference laboratory, to verify purity, sterility, and absence of contaminants including BVD virus.
• World Organisation for Animal Health (WOAH)moderateStrategic or Co-development PartnerCollaboration with WOAH to develop international standards for ASF vaccines. Vietnam, as first country to produce ASF vaccine commercially, is working with WOAH to establish global ASF vaccine standards.
• Central Veterinary Drugs Testing Centre (Vietnam)coreStrategic or Co-development PartnerPartnership for vaccine quality testing and standardization development for ASF vaccine use on breeding pigs. Working with the centre in 2024 to establish evaluation standards.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• NAVETCO (National Veterinary Joint Stock Company): Vietnamese state-affiliated veterinary vaccine manufacturer producing vaccines for swine, poultry, and cattle. Directly comparable as a domestic peer with overlapping product portfolio (mentioned alongside AVAC in farmer vaccination programs).

Regional players

• Botswana Vaccine Institute (BVI): African veterinary vaccine manufacturer with focus on cattle and livestock diseases including LSD. Comparable as a regional vaccine producer serving African markets where AVAC is pursuing registration (Tanzania).
• MEVAC (Middle East for Vaccines): Egyptian veterinary vaccine manufacturer focused on livestock and poultry vaccines for Middle East and African markets. Comparable as a regional animal vaccine producer with similar product categories and emerging market focus.

Broad incumbents

• Ceva Santé Animale: Global animal health company with significant presence in emerging markets and a broad livestock vaccine portfolio. Comparable as a multinational vaccine manufacturer with strong distribution in Southeast Asia and Africa where AVAC is expanding.
• Zoetis: Global leader in animal health and vaccines with broad livestock vaccine portfolio across species. Comparable as a large incumbent developing competing ASF vaccine candidates and offering the full range of swine and cattle vaccines AVAC competes against.
• MSD Animal Health: Major global animal health player with extensive veterinary vaccine portfolio including swine and cattle products. Relevant as a multinational competitor with the R&D resources to challenge AVAC in the ASF vaccine space.
• Phibro Animal Health: Diversified animal health and nutrition company with vaccine and pharmaceutical products for livestock. Comparable as a broader incumbent in animal health with overlapping livestock vaccine and pharmaceutical offerings.
• Boehringer Ingelheim Animal Health: Global animal health incumbent with leading swine vaccine portfolio (including PRRS vaccines). Comparable as a multinational competitor with established global distribution networks that AVAC is working to penetrate.

Emerging players

• HIPRA: Spanish veterinary pharmaceutical company specializing in animal vaccines with focus on swine and poultry. Comparable as a specialized animal vaccine company with similar product focus areas to AVAC.
• Indian Immunologicals: Indian veterinary vaccine manufacturer producing livestock and human vaccines. Comparable as an emerging market animal vaccine producer targeting similar disease segments in Asia.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/ctyavacvietnam

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AVAC Vietnam